The Food and Drug Administration Friday authorized the first molecular test to detect the SARS-CoV-2 virus in a nasal swab at home without a prescription. Cue Health expects by summer to daily produce more than 100,000 of the tests, authorized for use in patients age 2 and older.

The test has identified 96% of positive samples from people with symptoms and 100% of positive samples from people without symptoms. It includes a single-use test cartridge and nasal swab, reusable cartridge reader and mobile app, which in the future will allow users to report test results to public health authorities to monitor disease prevalence, FDA said.

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…